Oncology Central

Original story from UPMC Combining radiopharmaceutical and CAR T therapy shown to convert immune-resistant solid tumors into targets for CAR T cell therapy. Researchers at the University o...

In recent years, the treatment landscape for multiple myeloma has undergone a profound transformation, particularly with the emergence of B-cell maturation antigen (BCMA)-targeted therapies, which are providing unprecedented results. This eBook explores the new clinical challenges that BCMA therapies present, including how to expand post CAR T-cell therapy relapse option...

Original story from Queen Mary University of London Researchers have validated a rapid, non-invasive brush biopsy test for oral cancer. A paper publish...

US FDA approves palbociclib with trastuzumab, with or without pertuzumab, and endocrine therapy for the maintenance treatment of HR-positive, HER2-positive metastatic breast cancer. The Food and Drug Administration has approved palbociclib in combination with trastuzumab, with or without pertuzumab, and endocrine therapy for the maintenance treatment of ...

The Institute of Cancer Research, London, and The Royal Marsden NHS Foundation Trust have announced a new licensing agreement with MedTech company Mint Medical, a Snke Company, to improve monitoring for patients with bone disease in advanced prostate ca...